Publications
- Analysis of the Group of Pediatric Patients With Relapsing-Remitting Multiple Sclerosis: Data From the Czech National Registry2022 | Faculty of Medicine in Pilsen, Second Faculty of Medicine, Third Faculty of Medicine
- Subcutaneously delivered natalizumab for the treatment of highly active relapsing-remitting multiple sclerosis2022 | Faculty of Medicine in Hradec Králové
- Ofatumumab - a highly effective therapy for relapsing-remitting multiple sclerosis available in the first line2022 | Faculty of Medicine in Hradec Králové
- Ofatumumab and siponimod in the treatment of multiple sclerosis - case reports2022 | Faculty of Medicine in Hradec Králové
- Innate Immune System and Multiple Sclerosis. Granulocyte Numbers Are Reduced in Patients Affected by Relapsing-Remitting Multiple Sclerosis during the Remission Phase2020 | Faculty of Medicine in Hradec Králové, Second Faculty of Medicine
- Highly active relapse / reminent multiple sclerosis and okrelizumab after failure of alemtuzumab treatment2020 | Faculty of Medicine in Hradec Králové
- Alemtuzumab treatment in multiple slerosis: real clinical experience2019 | Faculty of Medicine in Hradec Králové
- Poruchy rovnováhy v dětském věku2023 | Faculty of Medicine in Hradec Králové, Second Faculty of Medicine, First Faculty of Medicine, Third Faculty of Medicine
- The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis2023 | Faculty of Medicine in Hradec Králové, Second Faculty of Medicine, First Faculty of Medicine
- Promising changes in dementia treatment2023 | Faculty of Medicine in Hradec Králové
Loading network view...